My Husband Knew My Wine Was Drugged—Then Told Me to Drink It Anyway.

Madison survived.

That mattered to me even though I hated what she had done.

She was taken to Baylor University Medical Center, where blood testing showed a sedating prescription drug in her system at a concentration inconsistent with the single sip she admitted taking unless the wine itself had contained a significant amount.

Residue recovered from the broken glass tested positive for the same substance.

My untouched blood sample did not.

By sunrise, Dallas police were treating the incident as possible intentional poisoning.

Ethan called me eleven times.

I answered none.

Lorraine sent one message.

You have humiliated this family beyond repair.

I forwarded it to my attorney, Nora Patel.

At 8:30 a.m., Nora arrived at my condo with coffee, a legal pad, and the expression she used whenever somebody had underestimated how much paperwork could destroy them.

I gave her the gala recording.

Then the corporate-card statement.

Three days before the event, Madison’s Whitmore Dynamics card had been used for a charge at a private concierge medical practice that normally served executives who wanted prescriptions delivered without visiting a pharmacy.

I had found the charge by accident while reviewing expenses connected to the acquisition.

“Why were you reviewing company cards?” Nora asked.

“Because I haven’t signed the sale consent.”

That was the part newspapers would not understand once the story broke.

Whitmore Dynamics was Ethan’s family company, but I owned 11.8 percent of the voting preferred shares.

Ten years earlier, when Ethan was still fighting to save the business after a disastrous expansion, my late father’s investment trust had provided $22 million in rescue financing. The loan later converted into preferred equity. When Dad died, those shares came to me.

They carried one unusual protection.

Any sale of substantially all company assets required my separate consent.

Ethan had spent four months trying to obtain it.

I had refused because numbers in Asteron’s data room did not reconcile.

“You think this is connected to the acquisition?” Nora asked.

“I don’t know.”

My phone rang.

Raymond Pierce.

The private-equity buyer.

I expected damage control.

Instead he said, “Claire, do not sign anything.”

My hand tightened around the phone.